

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claims 1-11 (Cancelled).

Claim 12 (Currently Amended): A nutritional or pharmaceutical composition for the inhibition of pathogenic bacteria adhesion to mammalian cells, or for reducing or inhibiting the invasion and infection of mammalian cells by pathogenic bacteria, wherein the mammal cells invaded or infected are mammalian gut or intestinal epithelial cells, the composition comprising:

a first compound ~~selected from the group consisting of comprising~~ methyl alpha manno-oligosaccharides, ~~partially hydrolysed guar gum, and combinations thereof, wherein the composition comprises in an amount of about 2.5% 0.5% to about 10% 50% of the first compound~~ by total weight of the composition; and

a second compound comprising proanthocyanidins.

Claim 13 (Currently Amended): The nutritional or pharmaceutical composition according to claim 12, wherein the ~~first compound is composition further comprises~~ partially hydrolysed guar gum.

Claims 14-15 (Cancelled).

Claim 16 (Currently Amended): A nutritional or pharmaceutical composition for the treatment of acute or chronic pathogenic bacteria-associated enteric disorders in a mammal, or for the treatment of pathogenic bacteria microflora proliferation in a mammal, the composition comprising:

a first compound selected from the group consisting of comprising methyl alpha manno-oligosaccharides, partially hydrolysed guar gum, and combinations thereof, wherein the composition comprises in an amount of about 2.5% 0.5% to about 10% 50% of the first compound by total weight of the composition: and

a second compound comprising proanthocyanidins.

Claim 17 (Previously Presented): The nutritional or pharmaceutical composition according to claim 16, wherein said acute or chronic pathogenic bacteria-associated enteric disorders are selected from the group consisting of gastroenteritis, ulcerative colitis, diarrhoeal diseases, and combinations thereof.

Claim 18 (Currently Amended): A method for inhibiting pathogenic bacteria adhesion to mammalian cells or for reducing or inhibiting the invasion and infection of mammalian cells by pathogenic bacteria, the method comprising administering to a mammal a composition comprising: a first compound selected from the group consisting of comprising methyl alpha manno-oligosaccharides, partially hydrolysed guar gum, and combinations thereof, wherein said mammalian cells are those of the gut and intestinal mammalian cells, and wherein the composition comprises about 2.5% 0.5% to about 10% 50% of the first compound by total weight of the composition; and a second compound comprising proanthocyanidins.

Claim 19 (Currently Amended): A method of treating acute or chronic pathogenic bacteria-associated, enteric disorders in a mammal, said method comprising administering to said mammal a composition comprising: ~~a therapeutically effective amount of a compound selected from the group consisting of about 0.5% to about 50% of methyl alpha manno-oligosaccharides, long chain isomalto oligosaccharides, and combinations thereof, wherein the composition comprises about 2.5% to about 10% of the compound~~ by total weight of the composition.

Claim 20 (Previously Presented): The method according to claim 19, wherein said enteric disorders are selected from the group consisting of gastroenteritis, ulcerative colitis, diarrhoeal diseases, and combinations thereof.

Claim 21 (Previously Presented): The method according to claim 19, wherein the composition further comprises a therapeutically effect amount of partially hydrolysed guar gum.

Claims 22-23 (Cancelled).

Claim 24 (Previously Presented): A nutritional or pharmaceutical composition comprising methyl alpha manno-oligosaccharides, wherein the composition comprises about 2.5% to about 10% of the methyl alpha manno-oligosaccharides by total weight of the composition.

Claim 25-26 (Cancelled).

Claim 27 (Withdrawn): A screening method to test the anti-adhesive activity of an oligosaccharide which method comprises:

adding oligosaccharide solution to cell monolayers of the human colonic cell line HT29 in triplicate wells,

adding an equal volume of bacterial culture,

c) washing of the cell layers after 2h at 37°C aerobic, 5% CO<sub>2</sub>,

detaching cell layers with trypsin/EDTA solution,

enumerating bacteria by plate counting, and

comparing counts in wells with oligosaccharides to those without.

Claim 28 (Currently Amended): A method for the manufacture of a nutritional or pharmaceutical composition for the inhibition of pathogenic bacteria adhesion to mammalian cells, or for reducing or inhibiting the invasion and infection of mammalian cells by pathogenic bacteria, the method comprising adding to the nutritional or pharmaceutical composition a first compound ~~selected from the group consisting of comprising methyl alpha manno-oligosaccharides, partially hydrolysed guar gum, and combinations thereof~~, wherein the mammalian cells are mammalian gut or intestinal epithelial cells, wherein the composition comprises about ~~2.5%~~ 0.5% to about ~~10%~~ 50% of the first compound by total weight of the composition; and adding to the nutritional or pharmaceutical composition a second compound comprising proanthocyanidin.

Claim 29 (Currently Amended): A method for the manufacture of a nutritional or pharmaceutical composition for the treatment of acute or chronic pathogenic bacteria-associated enteric disorders in a mammal or for the treatment of pathogenic bacteria microflora proliferation in the mammal, the method comprising adding to the nutritional or pharmaceutical composition a first compound ~~selected from the group consisting of comprising methyl alpha manno-oligosaccharides, partially hydrolysed guar gum, and combinations thereof~~, wherein the composition comprises about ~~2.5%~~ 0.5% to about ~~10%~~ 50% of the first compound by total weight of the composition; and adding to the nutritional or pharmaceutical composition a second compound comprising proanthocyanidins.

Claim 30 (Previously Presented): A method according to claim 29, wherein said enteric disorders are selected from the group consisting of gastroenteritis, ulcerative colitis, diarrhoeal diseases, and combinations thereof.

Claim 31 (Currently Amended): A method of treating acute or chronic pathogenic bacteria-associated, enteric disorders in a mammal, said method comprising administering to said mammal a composition comprising a therapeutically effective amount of ~~a compound selected from the group consisting of~~ caseinoglycomacropeptides (CGMP), ~~chito-oligosaccharides, and combinations thereof,~~ wherein the therapeutically effective amount of the compound is between about 1 g and about 15 g, and wherein the composition comprises a caloric content of less than about 1000 kcal.